6938-18-7

Basic information

• Product Name: 2-(4-hydroxyphenyl)-5,6,7-trimethoxy-4H-chromen-4-one
• Synonyms: 2-(4-Hydroxyphenyl)-5,6,7-trimethoxy-4H-1-benzopyran-4-one; 4H-1-benzopyran-4-one, 2-(4-hydroxyphenyl)-5,6,7-trimethoxy-; 4'-Hydroxy-5,6,7-trimethoxyflavone
• CAS NO: 6938-18-7
• Molecular Formula: C₁₈H₁₆O₆
• Molecular Weight: 328.316
• Mol File: 6938-18-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 548.8°C at 760 mmHg
• Flash Point: 202.1°C
• Density: 1.314g/cm³
• Vapor Pressure: 1.18E-12mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: 2-(4-hydroxyphenyl)-5,6,7-trimethoxy-4H-chromen-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-hydroxyphenyl)-5,6,7-trimethoxy-4H-chromen-4-one(6938-18-7)
• EPA Substance Registry System: 2-(4-hydroxyphenyl)-5,6,7-trimethoxy-4H-chromen-4-one(6938-18-7)

Safety Data

• Hazardous Substances Data: 6938-18-7(Hazardous Substances Data)

Usage

General Description

2-(4-hydroxyphenyl)-5,6,7-trimethoxy-4H-chromen-4-one, also known as hesperetin, is a flavonoid found in citrus fruits such as oranges and lemons. It has been studied for its potential health benefits, including antioxidant, anti-inflammatory, and anticancer properties. Hesperetin has also been shown to have potential therapeutic effects in the treatment of cardiovascular diseases, diabetes, and neurological disorders. Its chemical structure and properties make it a promising candidate for further research and potential use in pharmaceutical and nutraceutical applications.

Upstream product

• 6515-21-5 4-methoxymethoxy-benzaldehyde 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 59567-92-9 4,6′-dihydroxy-2′,3′,4′-trimethoxychalcone 
• 642-71-7 3,4,5-trimethoxyphenol 
• 59567-92-9 (E)-1-(6-hydroxy-2,3,4-trimethoxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one 
• 22248-14-2 6-hydroxy-2,3,4-trimethoxyacetophenone 
• 123-08-0 4-hydroxy-benzaldehyde 

Downstream Products

• 6601-62-3 salvigenin 

Relevant articles and documents

Synthesis and anti-proliferative activities of 5,6,7-trimethoxyflavones and their derivatives

A series of 5,6,7-trimethoxyflavones 1a-1g and their derivatives 2a-2g, 3a-3d, 4 and 5, including the natural products 5,6,7-trimethoxy-4’-hydroxyflavone (1a), 5,6,7,3’,4’ -pentamethoxyflavone (sinensetin, 1 b), 5,6,7-trimethoxy-3’,4’-methyl enedioxy flavone (1c), 5,6,7,3’-tetramethoxy-4,5’-methylenedioxyflavone (1e), 5,6,7, 3’,4’,5’-hextamethoxyflavone (1 g), 5-hydroxy-3,4,2’,3’,4’-pentamethoxy chal-cone (2 b), 5,4’-dihydroxy-6,7-dimethoxy flavone (cirsimaritin, 3a) and 5-hydroxy-6,7,3’, 4’-tetramethoxyflavone (5-demethylsinensetin, 3 b), 3,5,6,7,3’,4’-hexamethoxyflavone (3-methoxysinensetin, 4) and 5’-hydroxy-3,6,7,3’,4’-pentamethoxyflavone (5) were synthesized. Their anti-proliferative activity in?vitro was evaluated against a panel of four human cancer cell lines (Aspc-1, HCT-116, HepG-2 and SUN-5) by the CTG assay. The results showed that most of the synthetic compounds exhibited moderate to high anti-proliferative activities. In particular, compound 3c possess IC50 (5.30 μM) values below 10 μM against Aspc-1 cells and are worthy of further investigation.

Method used for synthesis of 6-hydroxyl-2, 3, 4-triethoxy-alpha-chloroacetophenone

The invention discloses a method used for synthesis of 6-hydroxyl-2, 3, 4-triethoxy-alpha-chloroacetophenone. According to the method, 3, 4, 5-trimethoxyphenol is taken as a raw material, a Lewis acidis taken as a catalyst, dichloromethane is taken as a r

Design, synthesis and biological evaluation of flavonoid salicylate derivatives as potential anti-tumor agents

A series of flavonoid salicylate derivatives containing trimethoxybenzene and a series of chrysin salicylate derivatives were synthesized for use as anti-tumor agents, and evaluated for antiproliferative activity using three human tumor cells: MCF-7 (breast carcinoma cells), HepG2 (liver carcinoma cells), MGC-803 (gastric carcinoma cells) and the mice tumor cells MFC (forestomach carcinoma cells). A substituent group of a suitable size and the trimethoxybenzene had a certain influence on the bioactivity of the flavonoid salicylate derivatives. Compound 2 and its salicylate derivatives 7a-7g containing the trimethoxybenzene exhibited more antiproliferative activity. Among them, compound 7g displayed the most potent antiproliferative activity against MGC-803 cells and MFC cells with the concentration causing 50% inhibition of cell growth (IC50) values of 11.05 ± 1.58 μM and 13.73 ± 2.04 μM, respectively. The flow cytometry results showed that compound 7g caused the cell cycle to be arrested in the G0/G1 phase and induced apoptosis of MFC cells in a dose-dependent manner. Furthermore, compound 7g showed good anti-tumor activity in vivo. These results suggested that compound 7g could be a new, potent anti-tumor candidate which should be optimized and evaluated further.